Michael T. Gundesen
Odense, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers.
Journal: British journal of haematology
Published: February 20, 2026
Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study.
Journal: Bone
Published: March 31, 2025
Treatment of myeloma bone disease: When, how often, and for how long?
Journal: Journal of bone oncology
Published: December 30, 2024
Home-Based Daratumumab in Patients With Multiple Myeloma.
Journal: European journal of haematology
Published: December 09, 2024
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma.
Journal: Haematologica
Published: August 20, 2024
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.
Journal: Oncotarget
Published: January 16, 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Journal: Blood cancer journal
Published: December 20, 2023
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Journal: Cancers
Published: October 24, 2023
Potential value of pre-planned imaging of bone disease in multiple myeloma.
Journal: Blood cancer journal
Published: December 06, 2022
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: December 02, 2022
Last Updated: 09/26/2026